Cochrane · systematic review · CD009744
Niacin for primary and secondary prevention of cardiovascular events
Schandelmaier, S, Briel, M, Saccilotto, R, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 3 · 50%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Niacin for primary and secondary prevention of cardiovascular events
Population: people with or at risk of cardiovascular disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall mortality ( | RR 1.05 [0.97, 1.12] | 12 studies · 35543 participants | High |
Cardiovascular mortality ( | RR 1.02 [0.93, 1.12] | 5 studies · 32966 participants | Moderate Downgraded: imprecision |
Non‐cardiovascular mortality ( | RR 1.12 [0.98, 1.28] | 5 studies · 32966 participants | High |
Fatal or non‐fatal myocardial infarction ( | RR 0.93 [0.87, 1] | 9 studies · 34829 participants | Moderate Downgraded: imprecision |
Fatal and non‐fatal stroke ( | RR 0.95 [0.74, 1.22] | 7 studies · 33661 participants | Low Downgraded: imprecision, inconsistency |
Discontinuation of treatment due to side effects ( | RR 2.17 [1.7, 2.77] | 17 studies · 33539 participants | Moderate Downgraded: inconsistency |